A ntiretroviral (ARV) therapy in human immunodeficiency virus(HIV)-infected infants and children has changed dramatically over the past several years, from monotherapy in the 1990s 1, 2 to the current use of combination regimens, including highly active ARV therapy (HAART). 3, 4 HAART has been associated with increased survival, reduction in opportunistic infections, improved growth and neurocognitive function, and improved quality of life. 3, [5] [6] [7] [8] [9] The goal of HAART is to achieve maximal suppression of viral replication to prevent disease progression, preserve immunologic function, and reduce the development of resistance while minimizing therapy-related side effects. A total of 16 ARV drugs have an approved pediatric treatment indication and are available as a pediatric formulation, tablet, or capsule size as of February 2009 (Table 1) . ARV treatment options are continually being updated because of availability of new medications, formulations, and dosing recommendations. Although this review summarizes the current information, US readers should refer to the Working Group Guidelines on Antiretroviral Therapy and Medical Management of HIV-Infected Children 10 for details, including the evidence basis for the treatment recommendations and future updates. International readers should refer to the World Health Organization and Pediatric European Network for Treatment of acquired immunodeficiency syndrome guidelines 11, 12 as well as locally applicable national and regional guidelines.
WHEN TO INITIATE THERAPY IN ARV-NAÏVE CHILDREN
The optimal timing of HAART initiation is unknown and continues to be controversial. Current trends suggest movement toward earlier treatment in adults that will likely influence recommendations for initiation in children. 13 Recommendations for initiation of therapy are more aggressive in children than adults because, particularly for infants, disease progression is more rapid and laboratory parameters less predictive of risk of progression. Studies of prognostic markers in children older than 12 months show that CD4% and plasma HIV RNA concentrations (viral loads) are both predictive of clinical progression or death, with CD4% being a stronger predictor than viral loads.
14 Risk of progression varies by age and CD4 count-associated risk of progression in children Ն5 years is similar to young adults. 14, 15 Thus, current recommendations for initiation of treatment designate 3 age groups: infants, children aged 1 to Ͻ5 years, and children aged Ն5 years.
Infants
On the basis of the results of the "Children with HIV Early Antiretroviral Therapy" clinical trial 16 that demonstrated significant reduction in mortality when asymptomatic young infants with normal CD4 percentages (Ͼ25%) were treated with HAART, prompt initiation of therapy is now recommended for all infants, regardless of clinical status, CD4%, or viral load. Studies have demonstrated that early initiation of HAART can result in durable viral suppression and normalization of immunologic responses in some infants.
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Symptomatic Children Aged >1 Year
For children 1 year of age or older, initiation of HAART is recommended for symptomatic infection (CDC clinical category B or C 18 or World Health Organization stage 3 or 4 12 ) regardless of CD4 count or percentage or viral load.
Asymptomatic or Mildly Symptomatic Children >1 Year of Age
Initiation of HAART in asymptomatic children 1 year of age or older is based on both CD4 counts or percentages and viral loads. The current recommendations are summarized in Table 2 .
SELECTION OF HAART IN NAÏVE PATIENTS
The current recommendation for initial HAART is to use 3 drugs from 2 classes of drugs: a backbone of 2 nucleoside analogue reverse transcription inhibitors combined with either a non-nucleoside reverse transcription inhibitor (NNRTI) or a protease inhibitor (PI). The optimal regimen depends on multiple factors including age; availability, and palatability of appropriate drug formulations; the potency, complexity, and toxicity of the regimen; prior ARV exposure as part of prevention of mother-to-child trans-mission interventions; and presence of drug resistance. Comorbidities that may affect drug choice, such as tuberculosis, hepatitis B or C virus infection, chronic renal or liver disease; and potential drug interactions with other medications taken by the child also should be considered. ARV drug resistance testing is recommended before initiation of therapy in all infants and children.
In the United States, the currently preferred nucleoside analogue reverse transcription inhibitors backbone is a combination of abacavir, didanosine, or zidovudine plus either lamivudine or emtricitabine. 10 HLA B*5701 genetic testing should be considered prior to initiating abacavir-based therapy, and abacavir should not be given to a child who tests positive. 19 A combination of tenofovir plus either lamivudine or emtricitabine also is preferred, but should only be considered in postpubertal adolescents because of concerns about possible effects on growing bones. 20 The selection between a NNRTIbased and a PI-based regimen remains equivocal. Currently, a trial comparing initial use of a nevirapine (NNRTI)-based and a lopinavir/ritonavir (PI)-based HAART regimen in HIV-infected infants is ongoing. Preliminary results from this study have demonstrated that infants exposed to nevirapine as part of prevention of mother-to-child transmission had inferior outcomes when treated with the nevirapine-based regimen. 21 No information is available to date for infants not exposed to nevirapine. Until these study findings are available, clinicians usually opt for a NNRTI or PI-based regimen based on their experience and individual patient characteristics.
Use of an NNRTI as initial therapy preserves the PI class for future use, and, less dyslipidemia and fat maldistribution have been reported with this class. 22 There is also a lower pill burden compared with PI-based regimens for children taking solid formula- If an NNRTI regimen is selected, the preferred agent is efavirenz for children age Ն3 years and nevirapine for children aged Ͻ3 years or who require a liquid formulation. 10 Seven PIs are currently approved for use in children and have pediatric drug formulations. The preferred PI is lopinavir coformulated with ritonavir.
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ASSESSING READINESS TO START AND ABILITY TO SUSTAIN ADHERENCE TO HAART
Young children are dependent on their care providers for ARV therapy. Preparing and supporting a care provider of an HIVinfected child includes education about HIV, rationale for treatment, medication storage, dosage and side effects, technique of administration of medication and, most importantly, adherence to the prescribed HAART regimen. Assessment of potential barriers to adherence is important not only before beginning HAART but throughout the treatment course. 25 Barriers to adherence can be related to medications (taste, volume/pill burden, frequency, side effects), logistics (food, shelter, transportation to clinic, competing priorities), or the care provider (mental health problems, substance abuse, denial of diagnosis, lack of disclosure). Assessing barriers and tailoring interventions accordingly are critical to long-term success. Many of the care providers are HIV-infected themselves and education of more than one care provider can be beneficial in providing consistent care despite the primary care providers' health and availability. Especially for infants, techniques of administration of medications and methods to mask the taste of medications are critical to treatment success.
SELECTION OF HAART IN PATIENTS WITH TREATMENT FAILURE
Treatment failure is categorized as virologic, immunologic, or clinical failure. Laboratory results must be confirmed with repeat testing before making a final assessment of virologic or immunologic treatment failure. Causes of treatment failure need to be assessed and addressed, and include drug resistance, poor absorption of medications, poor adherence, inadequate dosing, and drug-drug interactions.
New HAART regimens following treatment failure should be chosen based on treatment history and drug resistance testing. All prior resistance mutations and failing drug regimens should be considered when selecting a new regimen because some resistance mutations may not appear in the absence of selective pressure from a specific ARV. Management of drug resistance can be particularly challenging in treatment-experienced children, many of whom received monotherapy or other non-HAART regimens and have multiple resistance mutations present. Because of the complexities involved in selecting regimens for patients with treatment failure, referral to a pediatric HIV specialist is preferred.
In general, if a child has received initial therapy with an NNRTI-based regimen, change to a PI-based regimen is recommended and vice versa. Atazanavir, darunavir, fosamprenavir, each boosted with ritonavir, can be considered in a PI-based regimen for children Ն6 years of age after review of viral genotype. Additional options include ritonavir-boosted tipranavir and enfuvirtide (T-20), a fusion inhibitor as part of a 3-drug regimen. All of these agents have pediatric treatment indications for experienced patients with evidence of HIV replication. Enfuvirtide must be administered subcutaneously twice daily and is associated with a high incidence of local injection site reactions (98%).
In patients failing ARVs approved for their age, especially when clinical or immunologic deterioration occurs, use of investigational agents or agents approved for older age groups, can be considered. These include several new agents where sufficient pharmacokinetic and safety data for use in children are not available. Etravirine is an NNRTI that may retain antiviral activity even in the presence of a limited number of NNRTI resistance-associated mutations. Maraviroc is a CCR5 receptor antagonist that may be active against CCR5 positive virus but few data are available regarding its use in children. Raltegravir is an integrase inhibitor that is recommended for initial therapy in HIV-infected adults. It is currently being evaluated in treatment-experienced children, but pharmacokinetic, safety, and efficacy data are not yet available, and there is no commercially available pediatric formulation.
In some cases, drug resistance is so extensive that 2 fully active agents cannot be identified. In these patients, nonsuppressive regimens ("holding regimens") are sometimes used to prevent clinical and immunologic deterioration while waiting for additional active drugs to be available. This approach is acceptable but not ideal. 26, 27 These patients should be followed closely, and the potential to initiate a fully suppressive regimen should be constantly reassessed.
TOXICITIES AND MONITORING OF THERAPY
Side effects or intolerance to ARVs occur with moderate frequency. Drug-related toxicity may be acute, occurring soon after a drug has been administered; subacute, occurring within days of administration; or late, occurring after prolonged drug administra- 
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The Pediatric Infectious Disease Journal • Volume 29, Number 4, April 2010 tion. Severity may vary from mild to severe and life-threatening. Identification of the responsible agent allows substitution of a similar agent to which the virus is susceptible. Distinct adverse drug effects that are more commonly associated with certain ARV drugs or drug classes have been identified (Table 1 ). In general, mild and moderate toxicities do not require discontinuation of therapy or drug substitution; symptomatic treatment may be given. Some moderate toxicities may require the substitution with a drug in the same ARV class but with a different toxicity profile, or a drug in a different class, but do not require discontinuation of all therapy. Dose reduction is only recommended when drug levels have been determined to be excessive. Severe lifethreatening toxicity requires discontinuation of all ARV drugs and the initiation of appropriate supportive therapy. The drug associated with the toxicity can be substituted once the toxicity has resolved.
Children who initiate or change to a new HAART regimen need to be followed to assess effectiveness, adherence, tolerability, and side effects of the regimen. The child should be assessed within 1 to 2 weeks of initiating therapy, either in person or with a phone call, to assure proper administration of medications, evaluate clinical concerns, and support adherence. Baseline laboratory assessments should be done before initiation of therapy; these include CD4 count/percentage and viral load; complete blood count and differential; serum chemistries (electrolytes, BUN, creatinine, glucose, hepatic transaminases, calcium, and phosphorus); pancreatic enzyme evaluations (amylase, lipase), and serum lipid evaluation (cholesterol, triglycerides). The next evaluation should be within 4 to 8 weeks after initiating or changing therapy to assess potential adverse effects and adherence to medications. At this visit and every 3 to 4 months thereafter, effectiveness of therapy (measurement of CD4 count/ percentage and viral load) and laboratory evaluations for toxicity (complete blood count, serum chemistries, and renal and hepatic function tests) are assessed. Monitoring of drug toxicities should be tailored to the particular medications the child is taking. Finally the implications of long-term toxicities related to HIV and/or its treatment, such as cardiovascular morbidity and mortality, to the aging up cohort of pediatric HIV survivors, remains largely unknown.
In summary, progress in the treatment of pediatric HIV infection has been made over the past decade with significant reductions in morbidity and mortality. Understanding the principles of selecting HAART regimens and vigilance for toxicities are important for optimal management of HIVinfected infants and children. Where access to medications is not a problem, the biggest challenge to optimizing HAART is maintaining adherence to medications-a challenge that requires ongoing assessment and interventions as the patient moves from infancy to adolescence.
